Contact

News

Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

Press Release
Jul 22, 2025
ReAlta Life Sciences Publishes Data Demonstrating RLS-0071 (pegtarazimod) Reduces Brain Inflammation in Preclinical Hypoxic Ischemic Encephalopathy Model
ABSTRACT
Apr 25, 2025
Pharmacokinetics of RLS-0071, a Novel Anti-Inflammatory Peptide, in Newborns With Moderate or Severe Hypoxic Ischemic Encephalopathy
ABSTRACT
Apr 25, 2025
Early Granulocyte Inflammatory Biomarkers in Newborn Babies with Moderate or Severe Hypoxic Ischemic Encephalopathy
Press Release
Apr 25, 2025
ReAlta Life Sciences Announces New Clinical Data for RLS-0071 (pegtarazimod) from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting
Press Release
Jul 09, 2024
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Accomplished Financial Executive
Press Release
Aug 01, 2023
ReAlta Doses First Patient in Phase 2 STAR Study of RLS-0071 for HIE in Newborns
1 2 3 4